The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases

Brankin, E.; Walker, Mel; Lynch, Niall; Aspray, Terry; Lis, Y.; Cowell, Warren

doi:10.1185/030079906x112688

Cited by 57 publications

(45 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the management of several medical conditions, morec omplex dosing regimens have been related to problems with treatment continuity and poorer clinical outcome. [18][19][20][21] At the same time, some patients and physicians may prefer IR-MPH because it allows for greater ease in dose titration and permits morefl exible dosing schedules that may minimize side effects. 22 Of the ER-MPH products, OROS-MPH had the longest treatment continuity.This finding extends similar results concerning the continuity of MPH treatment for children and adolescents.…”

Section: Nn Discussionmentioning

confidence: 99%

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Olfson¹,

Marcus²,

Zhang³

et al. 2007

JMCP

View full text Add to dashboard Cite

ReseaRch Int he general adult population, the prevalence of attentiondeficit/hyperactivity disorder (ADHD) is approximately 2% to 4%. [1][2][3][4] Methylphenidate (MPH) effectively ameliorates many symptoms of adult ADHD. [5][6][7][8][9] In 1l arge 6-week randomized controlled trial of adults with ADHD,7 immediate-release methylphenidate (IR-MPH) was associated with a76% response rate, compared with a1 9% response rate for placebo. In a 6-week trial with the same response criteria, 66% of subjects treated with osmotic release oral system methylphenidate (OROS-MPH) responded, compared with 39% who received placebo. 9In both studies, response was defined as a3 0% symptom reduction and, at least, much overall improvement.Early discontinuation of treatment is common in the community careo fp atients initiating stimulant therapy. [10][11][12][13] In 1s tudy, BACKGROUND: Although stimulant therapyiscommonly discontinued early in adults with attention-deficit/hyperactivity disorder (ADHD), the factors that contribute to continuity of stimulant therapyremain largely unknown.OBJECTIVE: To (1) comparethe continuity of methylphenidate (MPH) therapy among adults who use immediate-release methylphenidate (IR-MPH) for ADHD with adults who use extended-release methylphenidate (ER-MPH) formulations, and (2) RESULTS: Less than one third(30.0%) of the adult patients who were prescribed MPH had 1ormoremedical claims with adiagnosis code for ADHD.For the adult MPH patients with at least 1medical claim with a diagnosis code for ADHD,the patients who initiated therapywith ER-MPH (N =2,833) weresignificantly younger,weremorelikely to be male,and were less likely to be treated by apsychiatrist than werethe patients who initiated therapywith IR-MPH (N =2,289). Only 50.5% (n =1,156) of IR-MPH patients and 61.4% (n =1,739) of ER-MPH patients had morethan 1pharmacyclaim for the indexMPH medication. Adults treated with ER-MPH also had a significantly longer median duration of treatment with the indexmedication (ER-MPH: 68 days, 95% confidence interval [CI], 65-71 days vs. IR-MPH 39 days, 95% CI, 33-52 days). Controlling for group differences in age,gender, treatment by apsychiatrist, recently prescribed psychotropic medications, treated mental disorders, emergencymental health treatment, and inpatient mental health care, ER-MPH initiation wasassociated with an average 27% longer duration of treatment than with IR-MPH (survival time ratio: 1.27, 95% CI, 1.20-1.35).CONCLUSION: In management of adult ADHD,use of ER-MPH formulations wasassociated with alonger median duration of the initially prescribed medication than wasuse of IR-MPH. It is unknown whether the observed absolute unadjusted difference of 29 days in median length of therapyis clinically important.

show abstract

Section: Nn Discussionmentioning

confidence: 99%

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Olfson¹,

Marcus²,

Zhang³

et al. 2007

JMCP

View full text Add to dashboard Cite

show abstract

“…MPR has been used elsewhere to assess compliance in GPRD data [24], and was defined in our study as the proportion of days within the first and the last prescription registered for which patients had prescription cover. Bisphosphonate non-users were imputed an MPR value of null.…”

Section: Compliance With Bisphosphonatesmentioning

confidence: 99%

Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Treatment compliance and persistence are important factors for any successful drug therapy. Several recent reports underline that a high compliance and persistence are associated with significantly higher reduction in risk of fractures in these populations [11][12][13][14][15][16]. Oral bisphosphonates are, however, associated with poor absorption, gastrointestinal adverse events and poor patient compliance [11,[17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

et al. 2011

View full text Add to dashboard Cite

show abstract

The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases

Cited by 57 publications

References 20 publications

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

Contact Info

Product

Resources

About